AstraZeneca: trials to resume next week?
(CercleFinance.com) - The clinical trials of Astrazeneca's Covid 19 potential vaccine, developed in collaboration with the University of Oxford, could resume next week, the Financial Times says.
According to the FT, the reason why the trials were stopped was a spinal cord problem in a British patient, Aurel BGC reports. This type of inflammation can occur as a result of a viral infection.
It remains to be shown that the vaccine is not the cause of this health problem, the broker said.
Remember that AstraZeneca yesterday confirmed a pause of phase 3 of its COVID-19 vaccine following the suspicion of a serious side effect.
It should be noted that Moderna and BioNTech, which are also in the running for the first authorised vaccine, have not paused their trials, Oddo says.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
According to the FT, the reason why the trials were stopped was a spinal cord problem in a British patient, Aurel BGC reports. This type of inflammation can occur as a result of a viral infection.
It remains to be shown that the vaccine is not the cause of this health problem, the broker said.
Remember that AstraZeneca yesterday confirmed a pause of phase 3 of its COVID-19 vaccine following the suspicion of a serious side effect.
It should be noted that Moderna and BioNTech, which are also in the running for the first authorised vaccine, have not paused their trials, Oddo says.
Copyright (c) 2020 CercleFinance.com. All rights reserved.